Terms: = Ovarian cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Treatment
625 results:
1. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
2. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
3. Combined inhibition of her2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
4. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
5. PARP Inhibitors in Breast cancer: a Short Communication.
Daly GR; AlRawashdeh MM; McGrath J; Dowling GP; Cox L; Naidoo S; Vareslija D; Hill ADK; Young L
Curr Oncol Rep; 2024 Feb; 26(2):103-113. PubMed ID: 38236558
[TBL] [Abstract] [Full Text] [Related]
6. Predictive and prognostic biomarkers in female genital tract tumours: an update highlighting their clinical relevance and practical issues.
Wong RW; Cheung ANY
Pathology; 2024 Mar; 56(2):214-227. PubMed ID: 38212229
[TBL] [Abstract] [Full Text] [Related]
7. Systemic treatment of Patients With Metastatic Breast cancer: ASCO Resource-Stratified Guideline.
Al Sukhun S; Temin S; Barrios CH; Antone NZ; Guerra YC; Chavez-MacGregor M; Chopra R; Danso MA; Gomez HL; Homian NM; Kandil A; Kithaka B; Koczwara B; Moy B; Nakigudde G; Petracci FE; Rugo HS; El Saghir NS; Arun BK
JCO Glob Oncol; 2024 Jan; 10():e2300285. PubMed ID: 38206277
[TBL] [Abstract] [Full Text] [Related]
8. Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in ovarian cancer SKOV3-TR Cells.
Lim YJ; Kim HS; Bae S; So KA; Kim TJ; Lee JH
Molecules; 2024 Jan; 29(1):. PubMed ID: 38202856
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/her2+ early-stage breast cancer patients who received trastuzumab: Evidence from a real-world study with long-term follow-up.
Ju J; Gao SL; Wang JY; Sang D; Kang YK; Wang X; Yue J; Shuai Y; Qi YX; Yuan P
Thorac Cancer; 2024 Feb; 15(6):439-447. PubMed ID: 38185807
[TBL] [Abstract] [Full Text] [Related]
10. Antibody-Drug Conjugates in Gynecologic cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract] [Full Text] [Related]
11. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract] [Full Text] [Related]
12. Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted treatment for her2+ Metastatic Gastric and Colorectal cancers.
Augustyniak M; Lou E; Jacobs G; Fleming M; Marshall J; Coutinho A; Yoshino T
J Cancer Educ; 2024 Apr; 39(2):118-125. PubMed ID: 38135836
[TBL] [Abstract] [Full Text] [Related]
13. Radiolabelled
Cieslik PA; Klingler S; Nolff M; Holland JP
Chemistry; 2024 Mar; 30(14):e202303805. PubMed ID: 38064536
[TBL] [Abstract] [Full Text] [Related]
14. Hybrid Membrane Camouflaged Chemodrug-Gene Nanoparticles for Enhanced Combination Therapy of ovarian cancer.
Chen T; Wang Y; Zhu L; Wu J; Lin J; Huang W; Yan D
ACS Appl Mater Interfaces; 2023 Dec; 15(50):58067-58078. PubMed ID: 38056905
[TBL] [Abstract] [Full Text] [Related]
15. Genomic and Molecular Characteristics of ovarian Carcinosarcoma.
Ramphal K; Hadfield MJ; Bandera CM; Hart J; Dizon DS
Am J Clin Oncol; 2023 Dec; 46(12):572-576. PubMed ID: 37986208
[TBL] [Abstract] [Full Text] [Related]
16. Antibody-Drug Conjugates (ADC) in her2/neu-Positive Gynecologic Tumors.
McNamara B; Greenman M; Pebley N; Mutlu L; Santin AD
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959808
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With her2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F; Makker V; Oaknin A; Oh DY; Banerjee S; González-Martín A; Jung KH; Ługowska I; Manso L; Manzano A; Melichar B; Siena S; Stroyakovskiy D; Fielding A; Ma Y; Puvvada S; Shire N; Lee JY
J Clin Oncol; 2024 Jan; 42(1):47-58. PubMed ID: 37870536
[TBL] [Abstract] [Full Text] [Related]
18. her-2-Targeted Boron neutron Capture Therapy with Carborane-integrated Immunoliposomes Prepared via an Exchanging Reaction.
Kawasaki R; Oshige A; Yamana K; Hirano H; Nishimura K; Miura Y; Yorioka R; Sanada Y; Bando K; Tabata A; Yasuhara K; Miyazaki Y; Shinoda W; Nishimura T; Azuma H; Takata T; Sakurai Y; Tanaka H; Suzuki M; Nagasaki T; Ikeda A
Chemistry; 2023 Dec; 29(72):e202302486. PubMed ID: 37792507
[TBL] [Abstract] [Full Text] [Related]
19. Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study.
Heredia A; Walbaum B; Vidal M; Itriago L; Camus M; Dominguez F; Manzor M; Martínez R; Murature G; Muñiz S; Navarro M; Guerra C; Merino T; Medina L; Ibañez C; Ramirez K; Acevedo F; Sánchez C
Breast Cancer Res Treat; 2024 Jan; 203(1):173-179. PubMed ID: 37733187
[TBL] [Abstract] [Full Text] [Related]
20. The role of sialylation in gynecologic cancers.
Yang ST; Liu CH; Chao WT; Liu HH; Lee WL; Wang PH
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):651-654. PubMed ID: 37678990
[TBL] [Abstract] [Full Text] [Related]
[Next]
